Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Ax­some Ther­a­peu­tics’ nar­colep­sy drug AXS-12 hit the pri­ma­ry end­point in its Phase 3 EN­CORE tri­al, show­ing a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in the fre­quen­cy of cat­a­plexy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER